Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC

NCT03624231 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Squamous Cell Carcinoma of the Head and Neck

Interventions

DRUG: Durvalumab
DRUG: Tremelimumab
RADIATION: Radiotherapy

Sponsor

Ulrich Keilholz

Collaborators

[object Object]
[object Object]